CARVYKTI® (ciltacabtagene autoleucel) Approved by the E

New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse

...

Related Keywords

Japan , China , United States , New Jersey , American , Ying Huang , Hemophagocytic Lymphohistiocytosis , Medicinal Devices Agency , Janssen Cilag International , Johnson , Japan Ministry Of Health , Exchange Commission On , American Cancer Society , European Commission , Legend Biotech Corporation , Drug Administration , European Medicines Agency , Janssen Biotech Inc , Twitter , Linkedin , Legend Biotech , Chief Executive Officer , Janssen Biotech , Release Syndrome , Effector Cell Associated Neurotoxicity Syndrome , Macrophage Activation Syndrome , Risk Evaluation , Mitigation Strategy , Mediated Myelitis , Nerve Palsies , After Day , Maturet Cell , Prescribing Information , Boxed Warning , Breakthrough Therapy Designation , Orphan Drug Designation , Orphan Medicinal Products , Private Securities Litigation Reform Act , Annual Report , Exchange Commission , Study Comparing , Versus Pomalidomide , Participants With Relapsed , Lenalidomide Refractory Multiple Myeloma , Accessed March , Statistics About Multiple Myeloma , Markets ,